Sign Up
OverviewAPI
Bristol Myers Squibb (BMS) showcased diverse approaches to address unmet needs in multiple myeloma therapy at ASH 2023, presenting updated results from its pipeline. The company highlighted three programs including GPRC5D CAR T, novel CELMoD agent mezigdomide, and bispecific T cell engager alnuctamab PRINCETON. BMS also announced plans for a Phase 2 trial of BMS-986393 in patients with RRMM exposed to four or more classes of therapy, and emphasized its commitment to developing tailored treatment approaches through its protein degradation research platform.

Ask a question